Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma
Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma
复制标题
血浆巨噬细胞迁移抑制因子对肝细胞癌诊断及预后的有效性
DOI：
10.1002/ijc.25918
复制
发表时间：
2011-11-15
影响因子：
6.4
通讯作者：
Fan, Jia
中科院分区：
文献类型：
--
作者：
Zhao, Yi-Ming;Wang, Lu;Fan, Jia
我们进行了我们的研究，以确定是否血浆巨噬细胞移动抑制因子（MIF）水平在肝细胞癌（HCC）患者的诊断和预后价值。采用酶联免疫吸附试验（ELISA）和免疫组化法分别检测血浆和组织中MIF的表达。将血浆MIF水平与HCC发生率、临床病理特征和结局进行比较。分别采用受试者工作特征分析法和X-tile法确定相应训练队列血浆MIF水平诊断和预后的临界点，并在验证队列中进行验证。在一个独立的队列（80例HCC患者）中检测HCC患者术后血浆MIF水平。结果表明，MIF原位表达主要位于肝癌细胞的胞浆中。肿瘤内MIF表达与血浆MIF水平呈正相关（r=0.759，p < 0.01）。
We performed our study to determine whether plasma macrophage migration inhibitory factor (MIF) levels have diagnostic and prognostic value in hepatocellular carcinoma (HCC) patients. Enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry were used to measure the expression of MIF in plasma and tissues, respectively. Plasma MIF levels were compared to HCC occurrence, clinicopathological features and outcomes. Cutpoints of plasma MIF levels for diagnosis and prognosis were, respectively, determined by receiver operating characteristic analysis and X-tile in corresponding training cohort, and then were confirmed in the validation cohort. The postoperative plasma MIF levels of HCC patients were detected in an independent cohort (80 HCC patients). As a result, MIF expression in situ was mainly observed in the cytoplasm of HCC cells. Intratumoral MIF expression was positively correlated with plasma MIF levels (r=0.759, p